Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog

Hepatology Research

Volumn 41, Issue 12, 2011, Pages 1178-1188

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a,b   Murata, Masayuki ^a   Ohnishi, Hachiro ^a   Toyoda, Kazuhiro ^a   Taniai, Hiroaki ^a   Ihara, Takeshi ^b   Ikezaki, Hiroaki ^b   Hayashi, Takeo ^b   Kainuma, Mosaburo ^a   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Breakthrough hepatitis; Hepatitis B virus; Liver fibrosis; Nucleoside analog; Transient elastography

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELASTOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RIGIDITY; SINGLE DRUG DOSE;

EID: 82255194408     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00869.x     Document Type: Article

References (37)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
3. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
4. Nevens F, Main J, Honkoop P etal. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-63.
5. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
6. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7.
7. Furusyo N, Takeoka H, Toyoda K etal. Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study. World J Gastroenterol 2006; 12: 561-7.
8. Lai CL, Dienstag J, Schiff E etal. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
9. Allen MI, Deslauriers M, Andrews CW etal. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
10. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-81.
11. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002; 49: 436-46.
12. Wong VW, Vergniol J, Wong GL etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
13. Corpechot C, El Naggar A, Poujol-Robert A etal. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-24.
14. Ziol M, Handra-Luca A, Kettaneh A etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
15. Ogawa E, Furusyo N, Toyoda K etal. Transient elastography for patients with chronic hepatitis B and C virus infection: non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007; 37: 1002-10.
16. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-34.
17. Chan HL, Tsang SW, Liew CT etal. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406-12.
18. Lok AS, Zoulim F, Locarnini S etal. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
19. Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler. J Clin Microbiol 2001; 39: 1456-9.
20. Murata M, Furusyo N, Unno M etal. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17: 2945-52.
21. Lucidarme D, Foucher J, Le Bail B etal. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
22. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
23. Enomoto M, Mori M, Ogawa T etal. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: regression of liver stiffness during entecavir therapy. Hepatol Res 2010; 40: 853-61.
24. Wong GL, Wong VW, Choi PC etal. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther 2011; 16: 165-72.
25. Suzuki Y, Arase Y, Ikeda K etal. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 2003; 46: 164-70.
26. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
27. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
28. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-50.
29. Scotto G, Fazio V. Hepatitis B genotypes and response to adefovir treatment in patients with HBV chronic infection. J Infect 2010; 60: 399-401.
30. Furusyo N, Nakashima H, Kashiwagi K etal. Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. Am J Trop Med Hyg 2002; 67: 151-7.
31. Sugiyama M, Tanaka Y, Kato T etal. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44: 915-24.
32. Kobayashi M, Suzuki F, Akuta N etal. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 2010; 40: 125-34.
33. Gish RG, Lok AS, Chang TT etal. Entecavir therapy for up to 96weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
34. Foucher J, Chanteloup E, Vergniol J etal. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8.
35. Masuzaki R, Tateishi R, Yoshida H etal. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-61.
36. Arena U, Vizzutti F, Corti G etal. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4.
37. Castéra L, Foucher J, Bernard PH etal. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13369 examinations. Hepatology 2010; 51: 828-35.